Humanistic therapies versus treatment as usual for depression

Philippa Davies¹, Vivien Hunot¹, Theresa HM Moore¹, Deborah Caldwell², Hannah Jones³, Glyn Lewis², and Rachel Churchill¹

¹Academic Unit of Psychiatry, School of Social and Community Medicine, University of Bristol, Bristol, UK

²School of Social and Community Medicine, University of Bristol, Bristol, UK

³Cochrane Schizophrenia Group, The University of Nottingham, Nottingham, UK

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

1. To examine the effectiveness and acceptability of all humanistic therapies compared with treatment as usual/waiting list/attention placebo control conditions for acute depression.
2. To examine the effectiveness and acceptability of different humanistic therapy models (person-centred, gestalt, process-experiential, transactional analysis, existential and non-directive therapies) compared with treatment as usual/waiting list/attention placebo control conditions for acute depression.
3. To examine the effectiveness and acceptability of all humanistic therapies compared with different types of comparator (standard care, no treatment, waiting list, attention placebo) for acute depression.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Contact address: Rachel Churchill, Academic Unit of Psychiatry, School of Social and Community Medicine, University of Bristol, Cotham House, Cotham, Bristol, BS6 6JL, UK. rachel.churchill@ccdan.org. rachel.churchill@bristol.ac.uk.

Editorial group: Cochrane Depression, Anxiety and Neurosis Group.

Publication status and date: Edited (no change to conclusions), published in Issue 8, 2012.

CONTRIBUTIONS OF AUTHORS

Philippa Davies contributed to the design of the review and development of the protocol. She will be responsible for managing and writing the review.

Vivien Hunot provided theoretical and clinical expertise for designing this programme of linked reviews, drawing from her training and clinical practice as a psychotherapeutic counsellor and cognitive behavioural therapist in NHS primary care settings. She worked on protocol development, developing a search strategy and compiling data extraction forms, and wrote the protocols for each review. Along with Dr Rachel Churchill, she conducted the original review on which this programme is based.

Theresa Moore is managing the organisation of data for the 12 linked reviews of psychotherapies for depression including the search results, tracking of papers, and management of references for the project. She has developed the data collection forms. She designed the database and spreadsheets for data collection and has contributed to writing sections of the protocols and commented on text of the protocols.

Deborah Caldwell provided methodological and statistical advice for each of 12 linked protocols assessing the effects of different psychotherapies for depression. She contributed to the design of the data extraction form, drafted some sections of the protocols and commented on the protocol manuscripts. She designed the plan for the multiple treatment meta-analysis for the overview of reviews. Glyn Lewis provided a clinical perspective on 12 linked psychotherapies for depression protocols.

Rachel Churchill conceived, designed, secured funding for, and is managing this programme of linked reviews. She has worked on all aspects of the development of this project, including building a review team, protocol development, developing a search strategy and compiling data-extraction forms. Along with Dr Vivien Hunot, she conducted the original review on which this programme is based. She is guarantor of the individual reviews in this programme of work.

DECLARATIONS OF INTEREST

None known.

BACKGROUND

Description of the condition

Major depression is characterised by persistent low mood and loss of interest in pleasurable activities, accompanied by a range of symptoms including weight loss, insomnia, fatigue, loss of energy, inappropriate guilt, poor concentration and morbid thoughts of death (APA 2000). Somatic complaints are also a common feature of depression, and people with severe depression may develop psychotic symptoms (APA 2000).

Depression is the third leading cause of disease burden world-wide and is expected to show a rising trend over the next 20 years (WHO 2004; WHO 2008). A recent European study has estimated the point prevalence of major depression and dysthymia at 3.9% and 1.1% respectively (ESEMED/MHEDEA 2004). As the largest source of non-fatal disease burden in the world, accounting for 12% of years lived with disability (Ustun 2004), depression is associated with marked personal, social and economic morbidity, loss of functioning and productivity and creates significant demands on service providers in terms of workload (NICE 2009). Depression is also associated with a significantly increased risk of mortality (Cuijpers 2002). The strength of this association, even taking account of confounders such as physical impairment, health-related behaviours and socio-economic factors, has been shown to be comparable to, or greater than, the strength of the association between smoking and mortality (Mykletun 2009).

Description of the intervention

Clinical guidelines recommend pharmacological and psychological interventions, alone or in combination, in the treatment of moderate to severe depression (NICE 2009). Antidepressant pre-prescribing has increased dramatically in many Western countries over the last 20 years, mainly with the advent of selective serotonin reuptake inhibitors and newer agents such as venlafaxine. Antidepressants continue to be the mainstay of treatment for depression in health care settings (Ellis 2004, NICE 2009).

Whilst antidepressants are of proven efficacy for the acute treatment of depression (Guaiana 2007; Arroll 2009; Cipriani 2009a; Cipriani 2009b; Cipriani 2009c), adherence rates remain very low (Hunot 2007; van Geffen 2009), due in part to patients' concerns about side effects and possible dependency (Hunot 2007). Furthermore, surveys consistently demonstrate patients' preference for psychological therapies over that of antidepressants (Churchill 2000; Riedel-Heller 2005). Therefore, psychological therapies provide an important alternative intervention for depressive disorders.

A diverse range of psychological therapies is now available for the treatment of common mental disorders (Pilgrim 2002). Psychological therapies may be broadly categorised into four separate philosophical and theoretical schools, comprising psychoanalytic/dynamic (Freud 1949; Klein 1960; Jung 1963), behavioural (Watson 1924; Skinner 1953; Marks 1981), humanistic (Maslow 1943; Rogers 1951; May 1961) and cognitive approaches (Lazarus 1971; Beck 1979). Each of these four schools contains a number of differing and overlapping psychotherapeutic approaches. Some psychotherapeutic approaches explicitly integrate components from several theoretical schools (e.g. cognitive analytic therapy (Ryle

1990)), or have been developed to address specific characteristics associated with particular disorders (e.g. interpersonal therapy for depression (Klerman 1984)).

During the first half of the twentieth century, psychology had been dominated by two schools of thought, behaviourism and psychoanalysis. Humanistic psychological therapies were developed in the 1950s and 60s as a protest against the diagnostic and pre-scriptive approaches characterised by the analytic and behavioural schools (Thorne 2007). These so-called 'third force' psychology approaches (Maslow 1959) brought about a paradigm shift, away from the 'psychological determinism' (the philosophical view that human cognition, behaviour, decision, and action, is causally determined by events, and implying a lack of free will) and towards client choice and responsibility (Pilgrim 2002). Key psychological therapies considered as humanistic in approach include Gestalt therapy (Perls 1976), existential therapy (van Deurzen 1997), transactional analysis (Berne 1961), person-centred therapy (Rogers 1951), and process-experiential therapy (a manualised humanistic intervention combining person-centred therapy and emotion-focused therapy) (Greenberg 1998). To date, person-centred therapy remains the most commonly used psychotherapeutic approach in UK health care settings (Stiles 2008) (see Types of interventions section for a detailed description of each type of therapy).

How the intervention might work

Humanistic psychological therapies are based on the premise that people are 'self-actualizing', that is, they have an inherent tendency to develop their potential (Rogers 1951, Maslow 1970). Other defining characteristics of humanistic therapies include the belief that people are self-aware, are free to choose how they will live, are responsible for the choices they make, and are unique entities that need to be understood in the context of their individual experiences and characteristics (Cain 2002).

In clinical practice, manualised or highly specific treatments for psychological disorders are largely avoided by humanistic therapists, on the basis that therapy should be individualised to fit with the personal goals, preferences and values of each client. Whilst contemporary models of humanistic therapies may differ some-what from a conceptual perspective and in terms of strategies/techniques, all emphasise the 'growth-inducing power' (Cain 2002) of the therapeutic relationship. Therapist 'core conditions' of empathy, genuineness and unconditional positive regard, described by Rogers 1951 as 'the definable climate of facilitative psychological attitudes', are considered as cornerstones of therapy. Creation of an optimal interpersonal environment to facilitate client insight, leading to acceptance, change and personal growth with resulting potential for a reduction in depression symptoms (Cain 2002). Presenting problems are person rather than disorder-focused, and individuals are treated as experts in their psychological distress. Whilst formal reduction in symptoms is not regarded as a goal in humanistic therapies practice, depression symptoms may decrease or remit as the client experiences increased self-acceptance and personal growth.

Why it is important to do this review

Clinical guidelines recommend cognitive behavioural therapy (CBT) and interpersonal therapy as first-line treatments for people with moderate to major depressive disorder

(Ballenger 2001; NICE 2009) with counselling (which may include humanistic, psychodynamic, or cognitive behavioural approaches, applied discretely or integratively) recommended for mild depression. The evidence-base for humanistic therapy approaches in the treatment of common mental disorders in general, and specifically in depressive disorders, is less extensive than for CBT-oriented therapies. Furthermore, the frequent use of 'non-directive' or 'supportive' therapies as 'attention placebo' conditions in randomised controlled trials of psychological therapies suggests they may not always be delivered as a 'bona fide' form of the therapy, and may be vulnerable to researcher allegiance (Cooper 2008). Previous systematic reviews of humanistic therapies do not provide a robust basis for decision-making, being limited to person-centred/experiential therapies (Elliott 2009), having combined a group of heterogeneous supportive therapy approaches (Churchill 2001; Cuijpers 2008), having presented only a narrative summary (Greenberg 2006), or having not made head to head comparisons (Elliott 2009).

Given that a high proportion of therapists and counsellors employed in UK primary care settings continue to use a person-centred approach (Stiles 2008), comprehensive review and meta-analysis of currently available evidence is called for to ensure that as far as possible it successfully represents and informs future health care policy and clinical practice in the treatment of depressive disorders. Furthermore, acknowledging the diversity of approaches under the umbrella of humanistic psychological therapies, an evaluation of the efficacy of different humanistic approaches will be of considerable value. This review forms part of a programme of 12 reviews covering behavioural, cognitive behavioural, psychodynamic, interpersonal, cognitive analytic and other integrative, humanistic and mindfulness-based 'third wave' cognitive and behavioural psychological therapies, all compared with treatment as usual or with one another.

OBJECTIVES

1. To examine the effectiveness and acceptability of all humanistic therapies compared with treatment as usual/waiting list/attention placebo control conditions for acute depression.
2. To examine the effectiveness and acceptability of different humanistic therapy models (person-centred, gestalt, process-experiential, transactional analysis, existential and non-directive therapies) compared with treatment as usual/waiting list/attention placebo control conditions for acute depression.
3. To examine the effectiveness and acceptability of all humanistic therapies compared with different types of comparator (standard care, no treatment, waiting list, attention placebo) for acute depression.

METHODS

Criteria for considering studies for this review

Types of studies—Randomised controlled trials (RCTs) will be eligible for inclusion in the review. Trials employing a cross-over design will be included in the review (whilst

acknowledging that this design is rarely used in psychological therapy trials), using data from the first active treatment stage only. Cluster RCTs will also be eligible for inclusion.

Quasi-randomised controlled trials, in which treatment assignment is decided through methods such as alternate days of the week, will not be eligible for inclusion.

Types of participants

Participant characteristics: Studies of men and women aged 18 years will be included. A Cochrane review on psychotherapy for depression in children and adolescents (<18 years) has been undertaken separately and is soon to be published (Watanabe 2004). The increasing prevalence of memory decline (Ivnik 1992), cognitive impairment (Rait 2005) and multiple comorbid physical disorders/polypharmacy (Chen 2001) in individuals over 74 years may differentially influence the process and effect of psychological therapy interventions. Therefore, to ensure that older patients are appropriately represented in the review (Bayer 2000; McMurdo 2005), an upper age cut-off of <75 years will be used (when a study may have included individuals 75, we will include it so long as the average age is <75), and a previously published Cochrane review on psychotherapeutic treatments for older depressed people (Wilson 2008) will be updated concurrently by the authors.

Setting: Studies may be conducted in primary care and community-based settings, or in secondary or specialist settings, and will include referrals as well as volunteers. Studies involving inpatients will be excluded. Studies that focus on specific populations - nurses, care givers, depressed participants at a specific work place - will be included if the participants all meet the criteria for depression.

Diagnosis: We will include all studies that focus on acute phase treatment of clinically diagnosed depression.

1. Studies adopting any standardised diagnostic criteria to define participants suffering from an acute phase unipolar depressive disorder will be included. Accepted diagnostic criteria include Feighner criteria, Research Diagnostic Criteria, DSM-III (APA 1980), DSM-III-R (APA 1987), DSM-IV-TR (APA 2000) or ICD-10 (WHO 1992) criteria. Earlier studies may have used ICD-9 (WHO 1978), but ICD-9 is not based on operationalised criteria, so studies using ICD-9 will be excluded from this category.
2. Mild, moderate and severe depressive disorders are all found in primary care (Mitchell 2009; Rait 2009; Roca 2009). In order to fully represent the broad spectrum of severity of depressive symptoms encountered by healthcare professionals in primary care, studies that used non-operationalised diagnostic criteria or used a validated clinician or self-report depression symptom questionnaire, such as Hamilton Rating Scale for Depression (Hamilton 1960) and Beck Depression Inventory (Beck 1961), to identify depression caseness based on a recognised threshold, will also be included. However, the influence of including this category of studies will be examined in a sensitivity analysis.

Accepted strategies for classifying mild, moderate and severe depression will be employed based, where possible, on those criteria used in the evidence syntheses underpinning the NICE 2009 guidelines for depression.

Studies involving participants with a diagnosis of chronic depression or treatment resistant depression, i.e. studies that list these conditions as inclusion criteria, will be excluded from the review. Studies in which participants are receiving treatment to prevent relapse following a depressive episode (that is, where participants are not depressed at study entry) will also be excluded.

Studies of people described as ‘at risk of suicide’, or with dysthymia or other affective disorders such as panic disorder will be included if the participants meet criteria for depression as stated above, but will be excluded if not.

We will not include subgroup analyses of people with depression, selected out of people with mixed diagnoses, because such studies would be susceptible to publication bias (the authors reported such subgroup studies because the results were “interesting”). In other words we will include such studies only if the inclusion criteria for the entire study satisfied our eligibility criteria.

Comorbidity: Studies involving participants with comorbid physical or common mental disorders will be eligible for inclusion, as long as the comorbidity is not the focus of the study. In other words, we will exclude such studies which focused on depression among patients with Parkinson’s disease or after acute myocardial infarction but will accept such studies which may have included some subjects with Parkinson’s disease or with acute myocardial infarction.

Types of interventions

Experimental interventions: The review recognises the overlap between different orientations (Sanders 2007) and the variations even within specific orientations, such as person-centred or gestalt therapy (Cooper 2008). Whilst acknowledging this variation and overlap, humanistic therapy approaches will be grouped into six main categories based on the theoretical principles set out by trial authors.

1. Person-centred therapy (Rogerian or client-centred therapy): In person-centred therapy (PCT), core conditions of empathy, genuineness and unconditional positive regard, considered to be the ‘antithesis’ of a therapeutic technique (Cooper 2008) are considered sufficient to facilitate personality change (Rogers 1951). Use of a non-directive stance by the therapist is a key feature of PCT (Mearns 2007). Moving through three phases of trust, intimacy and mutuality within the therapeutic relationship (Mearns 2007), change occurs as the client shifts from a negative evaluation of self towards a belief that they are worth caring for (Thorne 2002).

2. Gestalt therapy: Gestalt therapy focuses on the process of human contact, described as the contact or ‘need cycle’ (Strumpf 2006). The cycle begins with an emotional impulse and is completed when the need is gratified and assimilated. Disturbances to the contact

cycle, such as the belief that 'I am not allowed to get angry', are seen as the basis of pathology and become the focus of therapy (Strumpf 2006). Gestalt therapists support and provoke exploration of disturbances within the 'here and now' experience of the therapeutic encounter, with the aim of resolving the disturbance and helping the client to complete the contact cycle. Originally conducted using a confrontational style (Perls 1976), Gestalt therapy models have become 'softer' and more dialogue-based (Yontef 1998). Experiments remain a central tenet of Gestalt therapy approaches, through use of a range of techniques such as exaggeration (repeating and intensifying a particular behaviour to bring unconscious emotional processes into awareness), dramatising (assuming roles of influential people in clients' lives through staging family scenes), artwork, dance/other physical movement and two-chair/empty chair work (exploration of conflict within the client) as part of the experiential learning process (Strumpf 2006).

3. *Experiential therapies:* Experiential therapies, include focused-oriented psychotherapy (Gendlin 1996) and emotion-focused therapy, manualised as process-experiential therapy (Greenberg 2005). Focus-oriented psychotherapy integrates 'levels of interventiveness' techniques (the degree on which a therapist brings in material from outside the client's frame of reference, and the degree to which this is done from the stance of authority or expertise) (Warner 2000) with Rogers' therapeutic conditions to help clients to attend to their moment-by-moment experiencing, and so enhance insight and therapeutic change. Similarly, process-experiential therapy, still in development, uses techniques such as two-chair and empty chair dialogue, drawn from gestalt therapy and cognitive/information processing psychology to enable here and now experiencing of emotional processes (Sanders 2007).

4. *Transactional analysis:* Whilst drawing from a broad range of influences, including psychodynamic, cognitive behavioural and existential theory, transactional analysis is considered essentially to be consistent with core beliefs of humanistic psychology theory and practice (Berne 1961; Tudor 2002). The primary goal of transactional analysis is the creation of a meaningful working alliance, within which transformation and development can occur. Ego states, transactions, scripts and games are cornerstones of transactional analysis theory and practice, and these may be explored using eight sequential 'therapeutic operations' of interrogation, specification, confrontation, explanation, illustration, confirmation interpretation and crystallisation, once the working alliance has been established (Tudor 2002).

5. *Existential therapy:* Existential therapy is described as a rich tapestry of intersecting therapeutic practices, all of which orientate themselves around the shared concern of 'human lived existence' (Cooper 2003). In clinical practice, existential therapists have a preference for autonomous, individualised approaches with clients rather than a single all-encompassing system (Cooper 2003). In Yalom's existential therapy (Yalom 1980), clients are encouraged to confront four ultimate existential concerns of death, freedom, isolation and meaninglessness. In contrast, van Deurzen's approach explores four dimensions of worldly being, consisting of physical, personal, social and spiritual dimensions (van Deurzen 2002). In other existential therapy approaches, practitioners work with clients to

focus in on subjective experiences (Bugental 1978) or to focus out on their responsibilities to others (Frankl 1984).

6. *Non-directive/supportive therapies:* Therapies described as ‘non-directive’ or ‘supportive’, and not explicitly underpinned by humanistic theory, principles and supporting references, will be included in the review. The impact of their inclusion will be examined in sensitivity analyses (see Methods section).

7. *Other humanistic therapies:* Where studies of other humanistic therapy approaches not listed above are identified, a post-hoc decision will be made about their inclusion in the review, and the impact of their inclusion will be examined in a sensitivity analysis (see Methods section).

Comparators: The control comparison will be ‘treatment as usual’ (also called standard care, usual care or no treatment; TAU), waiting list (WL), attention placebo (AP) and psychological placebo (PP). The type of ‘treatment as usual’ comparator used is likely to influence the observed effectiveness of the intervention and, where possible, for the purposes of heterogeneity analyses, comparators will be subgrouped as waiting list, treatment as usual/usual care or attention placebo. In each study, descriptions of ‘treatment as usual’ and attention placebo conditions will be scrutinised to ensure that they do not comprise an active psychological therapy treatment. Within the ‘treatment as usual’ and waiting list conditions, participants may receive any appropriate medical care during the course of the study on a naturalistic basis, including pharmacotherapy and/or psychological therapy, as deemed necessary by the clinician. Additional treatment(s) received naturalistically by participants in both the control and active comparisons for each included study will be documented.

Format of psychological therapies: The psychological therapy intervention is required to be delivered through face to face meetings between the patient and therapist. Interventions in which face to face therapy is augmented by telephone or Internet-based support will be included in the review. Psychological therapy approaches conducted on either an individual or on a group basis will be eligible for inclusion. There is no limit to the number of sessions and we will accept psychological therapy delivered in only one session.

Excluded interventions: Counselling interventions traditionally draw from a wide range of psychological therapy models, including person-centred, psychodynamic and cognitive behavioural approaches, applied integratively, according to the theoretical orientation of practitioners (Stiles 2008). Therefore, studies of counselling will usually be included in the integrative therapies reviews. However if the counselling intervention consists of a single discrete psychological therapy approach, it will be categorised as such, even if the intervention is referred to as ‘counselling’. If the intervention is manualised, this will inform our classification.

Psychological therapy models based on social constructionist principles (that focus on the ways in which individuals and groups participate in the construction of their perceived social reality) including couples therapy, family therapy, solution-focused therapy, narrative

therapy, personal construct therapy, neuro-linguistic programming and brief problem-solving (Watzlavick 1974) will be excluded. These therapies work with patterns and dynamics of relating within and between family, social and cultural systems in order to create a socially constructed framework of ideas (O'Connell 2007), rather than focusing on one individual's reality. Previously published Cochrane reviews on couples therapy for depression (Barbato 2006) and family therapy for depression (Henken 2007) will be updated concurrently.

Studies of long-term, continuation or maintenance therapy interventions designed to prevent relapse of depression or to treat chronic depressive disorders will be excluded from the review. Similarly, studies of interventions designed to prevent a future episode of depression will be excluded.

Guided self-help, in which the practitioner provides brief face to face non-therapeutic support to patients who are using a self-help psychological therapy intervention, will be excluded as will bibliotherapy and writing therapies.

Psychological therapy that is provided wholly by telephone or over the Internet will not be eligible for inclusion.

Studies of dual modality treatments, in which patients are randomised to receive a humanistic therapy intervention combined with pharmacological treatment and compared with a treatment as usual control condition, will be excluded from the current review, and will be examined in a separate programme of reviews on combination treatments for depression.

Component or dismantling studies, in which the effectiveness of individual components of a humanistic therapy approach are investigated, will not be included. Data from these studies will be extracted and included in a separate overview of psychological therapies for depression, in which multiple treatments meta-analysis (MTM) will be used to compare the relative effectiveness of all psychotherapies, regardless of whether they have been directly compared in direct RCTs. If there is sufficient data, we will use the MTM model proposed in Welton 2009 to allow conclusions to be drawn regarding which components, or combination of components, are most effective at reducing depressive symptoms. See Unit of analysis issues for further detail on MTM.

Types of outcome measures

Primary outcomes

1. Treatment efficacy: the number of patients who respond to treatment, based on changes on Beck Depression Inventory (BDI) (Beck 1961), Hamilton Rating Scale for Depression (HAM-D) (Hamilton 1960) or Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery 1979), or any other validated depression scale. Many studies define response by 50% or greater reduction on BDI, HAM-D etc. but some studies define response using Jacobson's Reliable Change Index; we will accept the study authors' original definition. If the original authors report

several outcomes corresponding with our definition of response, we will give preference to BDI for self-rating scale and HAM-D for observer-rating scale.

2. Treatment acceptability: the number of participants who drop out of psychological therapy treatment for any reason.

Secondary outcomes

1. The number of patients who remit on treatment, based on the endpoint absolute status of the patients, as measured by Beck Depression Inventory (BDI) (Beck 1961), Hamilton Rating Scale for Depression (HAM-D) (Hamilton 1960) or Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery 1979), or any other validated depression scale. Examples of definitions of remission include 10 or less on BDI, 7 or less on HAM-D or 10 or less on MADRS; we will accept the study authors' original definition. If the original authors report several outcomes corresponding with our definition of response, we will give preference to BDI for self-rating scale and HAM-D for observer-rating scale.
2. Improvement in depression symptoms, based on a continuous outcome of group mean scores at the end of treatment using BDI, HAM-D, MADRS, or any other validated depression scale.
3. Improvement in overall symptoms, using the Clinical Global Impressions scale (CGI) (Guy 1976).
4. Improvement in anxiety symptoms, measured using a validated continuous scale, either assessor-rated, such as the Hamilton Anxiety Scale (HAM-A) (Hamilton 1959) or self-report, including the Trait subscale of the Spielberger State-Trait Anxiety Inventory (STAI-T) (Spielberger 1983) and the Beck Anxiety Inventory (BAI) (Beck 1988).
5. Adverse effects, such as completed suicides, attempted suicides and worsening of symptoms, where reported, will be summarised in narrative form.
6. Social adjustment, social functioning including the Global Assessment of Function (Luborsky 1962) scores, where reported, will be summarised in narrative form.
7. Quality of life, using validated measures such as the SF-36 (Ware 1993), HoNOS (Wing 1994) and WHOQOL (WHOQOL 1998), where reported, will be summarised in narrative form.
8. Economic outcomes (e.g. days of work absence/ability to return to work, number of appointments with primary care physician, number of referrals to secondary services, use of additional treatments) where reported, will be summarised in narrative form.

Search methods for identification of studies

Electronic searches

CCDANCTR Registers: We will search two clinical trials registers created and maintained by the Cochrane Depression, Anxiety and Neurosis Group (CCDAN), the CCDANCTR-

Studies Register and the CCDANCTR-References Register. References to trials for inclusion in the Group's registers are collated from routine (weekly) searches of MEDLINE, EMBASE and PsycINFO, quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and additional *ad hoc* searches of other databases (PSYINDEX, LILACS, AMED, CINAHL). These searches employ generic terms for depression anxiety and neuroses; together with sensitive (database specific) RCT filters.

References to trials are also sourced from international trials registers via the World Health Organisation's trials portal (<http://apps.who.int/trialsearch/>); drug companies; the hand-searching of key journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses.

Details of the generic search strategies can be found in the 'Specialized Register' section of the Cochrane Depression, Anxiety and Neurosis Group's [module text](#).

1. The CCDANCTR-Studies Register: The CCDANCTR-Studies Register contains over 11,000 trials for the treatment or prevention of depression, anxiety and neurosis. Each trial has been coded using the [EU-Psi coding manual](#) (as a guide) and includes information on intervention, condition, comorbidities, age, treatment setting etc.

The studies register will be searched using the following search terms:

Condition = (depress* or dysthymi*) and Intervention = (*therap* or training)

2. The CCDANCTR-References Register: The CCDANCTR-References Register contains bibliographic records of reports of trials coded in the CCDANCTR-Studies Register together with several other uncoded references (total number of records=24,500). This register will be searched using a comprehensive list of terms for 'psychotherapies' as indicated in Appendix 1. Records already retrieved from the search of the CCDANCTR-Studies Register will be de-duplicated.

Searching other resources

1. Reference lists: The references of all selected studies will be searched for more published reports and citations of unpublished studies. Relevant review papers will be checked.

2. Personal communication: Subject experts will be contacted to check that all relevant studies, either published or unpublished, have been considered for inclusion.

Data collection and analysis

Selection of studies—Two review authors (RC and VH) will examine the abstracts of all publications obtained through the search strategy. Full articles of all the studies identified by either of the review authors will then be obtained and inspected by the same two review authors for trials meeting the following criteria:

1. Randomised controlled trial;
2. Participants have depression diagnosed by operationalised criteria; and

3. Any humanistic therapy approach, to include supportive or non-directive placebo control therapies, versus non-treatment, waiting list control or treatment as usual.

Conflicts of opinion regarding eligibility of a study will be discussed with a third review author, having retrieved the full paper and consulted the authors if necessary, until consensus is reached. External subject or methodological experts will be consulted if necessary.

Data extraction and management—Data will be extracted by two review authors, with data from each study being extracted independently by two of these authors. Any disagreement will be discussed with an additional review author and where necessary, the authors of the studies will be contacted for further information.

Information relating to study population, sample size, interventions, comparators, potential biases in the conduct of the trial, outcomes including adverse events, follow-up and methods of statistical analysis will be abstracted from the original reports into specially designed paper forms then entered into a spreadsheet.

Management of time points: Post-treatment outcomes and outcomes at each reported follow-up point will be summarised. Where appropriate and if the data allow, outcomes will be categorised as short term (up to 6 months post-treatment), medium term (7 to 12 months post-treatment) or long term (longer than 12 months).

Waiting list controls: A commonly used ‘treatment as usual’ is to randomise participants to active intervention groups and control group, to provide the active intervention to both groups but to delay delivery of the intervention to the control group until after those in the intervention group have completed treatment. Thus both groups receive the active intervention but at different times. Sometimes trialists describe this as a ‘Waiting list control’ or the control participants are placed ‘on a waiting list’.

Data are collected at baseline, when groups are randomised and at the ‘end-of-treatment’ at which point participants in the active intervention group stop receiving the active intervention and the participants on the waiting list *start* the active intervention. There may be a follow-up of participants at time points after the end-of-treatment.

For studies like this we will include data up to the time point at which the waiting list participants start to receive treatment. Follow-up data for these participants will not be used. To include follow-up data could introduce bias as the intervention is not as originally allocated at the point of randomisation and participants may no longer be comparable. For instance, baseline risk for participants who received delayed treatment may have changed (e.g. participants may be more depressed).

Assessment of risk of bias in included studies—Risk of bias will be assessed for each included study using the Cochrane Collaboration’s ‘risk of bias’ tool (Higgins 2008). The following six domains will be considered:

1. Sequence generation: Was the allocation sequence adequately generated?

2. Allocation concealment: Was allocation adequately concealed?
3. Blinding of participants, personnel and outcome assessors for each main outcome or class of outcomes: Was knowledge of the allocated treatment adequately prevented during the study?
4. Incomplete outcome data for each main outcome or class of outcomes: Were incomplete outcome data adequately addressed?
5. Selective outcome reporting: Are reports of the study free of suggestion of selective outcome reporting?
6. Other sources of bias: Was the study apparently free of other problems that could put it at a high risk of bias? Additional items to be included here are therapist qualifications, treatment fidelity and researcher allegiance/conflict of interest.

A description of what was reported to have happened in each study will be provided, and a judgement on the risk of bias will be made for each domain within and across studies, based on the following three categories:

- A. Yes (low risk of bias)
- B. Unclear
- C. No (high risk of bias).

Two review authors will independently assess the risk of bias in selected studies. Any disagreement will be discussed with a third review author. Where necessary, the authors of the studies will be contacted for further information. All risk of bias data will be presented graphically and described in the text. Allocation concealment will be used as a marker of trial quality for the purposes of undertaking sensitivity analyses.

Measures of treatment effect

Continuous outcomes: Where studies have used the same outcome measure for comparison, data will be pooled by calculating the mean difference (MD). Where different measures are used to assess the same outcome, data will be pooled with standardised mean difference (SMD) and 95% confidence intervals calculated.

Dichotomous outcomes: These outcomes will be analysed by calculating a pooled odds ratio (OR) and 95% confidence intervals for each comparison. Because ORs can be difficult to interpret, these pooled ORs will be converted to relative risks (RR) using the formula provided in The Cochrane Handbook (Higgins 2008) and presented in this form for ease of interpretation.

Unit of analysis issues—Studies with more than two intervention arms can pose analytical problems in pair-wise meta-analysis. Where studies have two or more active treatment arms to be compared against treatment as usual, data will be managed in this review as follows:

Continuous data: Means, SDs and number of participants for each active treatment group will be pooled across treatment arms as a function of the number of participants in each arm to be compared against the control group (Law 2003; Higgins 2008; Higgins 2008b).

Dichotomous data: Data from relevant active intervention arms will be collapsed into a single arm for comparison or data from relevant active intervention arms will be split equally between comparator arms.

Multiple treatment meta-analysis: One method which retains the individual identity of each intervention and allows multiple intervention comparisons to be made, without the need to lump or split intervention arms, is a multiple treatment meta-analysis (MTM) (Lu 2004; Caldwell 2005; Cipriani 2009c). MTM (also known as Mixed Treatment Comparison or Network Meta-analysis) refers to ensembles of trial evidence in which direct and indirect evidence on relative treatment effects are pooled. The objective of an MTM is to combine all the available trial evidence into an internally consistent set of estimates while respecting the randomisation in the evidence. An MTM provides estimates of the effect of each intervention relative to every other, whether or not they have been directly compared in trials. One can also calculate the probability that each treatment is the most effective. We do not intend to use an MTM in this review, as we are unlikely to have sufficient data for the analysis. However, this review forms part of a series of 12 reviews which will contribute studies to an overview of reviews (Higgins 2008a; Becker 2009) in which MTM will be used as the main analytical strategy.

Dealing with missing data—Missing dichotomous data will be managed through intention to treat (ITT) analysis, in which it will be assumed that patients who dropped out after randomisation had a negative outcome. Best / worse case scenarios will also be calculated for the clinical response outcome, in which it will be assumed that dropouts in the active treatment group had positive outcomes and those in the control group had negative outcomes (best case scenario), and that dropouts in the active treatment group had negative outcomes and those in the control group had positive outcomes (worst case scenario), thus providing boundaries for the observed treatment effect. If there is a large amount of missing information then these best / worst case scenarios will be given greater emphasis in the presentation of the results.

Missing continuous data will either analysed on an endpoint basis, including only participants with a final assessment, or analysed using last observation carried forward to the final assessment (LOCF) if LOCF data were reported by the trial authors. Where SDs are missing, attempts will be made to obtain these data through contacting trial authors. Where SDs are not available from trial authors, they will be calculated from P values, t-values, confidence intervals or standard errors, where reported in articles (Deeks 1997). Where the vast majority of actual SDs are available and only a minority of SDs are unavailable or unobtainable, a method used for imputing SDs and calculating percentage responders devised by Furukawa and colleagues (Furukawa 2005; Furukawa 2006) will be used. Where this method is employed, data will be interpreted with caution, taking account of the degree of heterogeneity observed. A sensitivity analysis will also be undertaken to examine the effect of the decision to use imputed data.

Where additional figures are not available or obtainable, and it is not deemed appropriate to use the Furukawa method described above, the study data will not be included in the comparison of interest.

Assessment of heterogeneity—Statistical heterogeneity will be formally tested using the χ^2 test, which provides evidence of variation in effect estimates beyond that of chance. Since the χ^2 test has low power to assess heterogeneity where a small number of participants or trials are included, the P value will be conservatively set at 0.1. Heterogeneity will also be quantified using the I^2 statistic, which calculates the percentage of variability due to heterogeneity rather than chance. We expect, a priori, that there will be considerable clinical heterogeneity between studies and so I^2 values in the range of 50% to 90% will be considered to represent substantial statistical heterogeneity and will be explored further. However, the importance of the observed I^2 will depend on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (Higgins 2003; Deeks 2008). Forest plots generated in RevMan 5 now also provide an estimate of τ^2 , the between-study variance in a random-effects meta-analysis. To give an indication of the spread of true intervention effects we will use the τ^2 estimate to form an approximate range of intervention effects using the method outlined in section 9.5.4 of the Cochrane Handbook for Systematic Reviews of Interventions (Deeks 2008). This will be undertaken for the primary outcomes only.

Assessment of reporting biases—As far as possible, the impact of reporting biases will be minimised by undertaking comprehensive searches of multiple sources (including trial registries), increasing efforts to identify unpublished material, and including non-English language publications.

We will also try and identify outcome reporting bias in trials by recording all trial outcomes, planned and reported and noting where there are missing outcomes. Where we find evidence of missing outcomes, we will attempt to obtain any available data direct from the authors.

Where sufficient numbers of trials allow for a meaningful analysis, funnel plots will be constructed to establish the potential influence of reporting biases and small study effects.

Data synthesis—Given the potential heterogeneity of psychological therapy approaches for inclusion, together with the likelihood of differing secondary comorbid mental disorders in the population of interest, a random-effects model will be used in all analyses.

Subgroup analysis and investigation of heterogeneity

Clinical heterogeneity

1. Baseline depression severity: the severity of depression on entering the trial is expected to have an impact on outcome. Heterogeneity analyses will categorise baseline severity as mild, moderate or severe.
2. Number of sessions: there are likely to be differences in the numbers of therapy sessions received and this is expected to affect treatment outcome. Numbers of

sessions will be categorised as 1 to 7 sessions, 8 to 12 sessions, 13 to 20 sessions and more than 20 sessions.

3. Type of comparison: the type of comparator used is likely to influence the observed effectiveness of the intervention. Where possible, comparators will be categorised as waiting list or treatment as usual/usual care or attention placebo.
4. Strength of therapeutic alliance/perceived therapist empathy, based on validated measures such as the Barrett-Lennard Relationship Inventory (Barrett-Lennard 1986) or Working Alliance Inventory (Horvath 1986): where reported, this information will be summarised in narrative form.

Sensitivity analysis

1. Fidelity to treatment: studies that have not assessed fidelity to the psychological therapy model(s) under evaluation through assessment of audio or videotapes of therapy sessions will be excluded
2. Study quality: allocation concealment will be used as a marker of trial quality. Studies that have not used allocation concealment will be excluded.
3. Trials where missing data has been imputed will be excluded.
4. Antidepressant treatment (naturalistic use; combination treatment used in both psychological therapy arms)
5. Trials included in the review following post-hoc decisions about their eligibility as a humanistic therapeutic approach will be excluded.

Acknowledgments

Internal sources

- University of Bristol, UK.

External sources

- Department of Health, UK.

NIHR Programme Grant

WHAT'S NEW

Date	Event	Description
20 June 2012	Amended	Minor changes to methods

HISTORY

Protocol first published: Issue 9, 2010

APPENDICES

Appendix 1. CCDAN-CTR References Register search (psychotherapies for depression)

Title, Abstract, Keywords = (depress* or dysthymi*)

and

Title, Abstract, Keywords = ((*therap* and ((acceptance* or commitment*) or “activity scheduling” or alderian or art or aversion or brief or “client cent*” or cognitive or color or colour or “compassion-focused” or “compassion* focus*” or compassionate or conjoint or conversion or conversational or couples or dance or dialectic* or diffusion or distraction or eclectic or “emotion* focus*” or emotion-focus* or existential or experiential or exposure or expressive or family or focus-oriented or “focus oriented” or freudian or gestalt or group or humanistic or implosive or insight or integrative or interpersonal or jungian or kleinian or marital or metacognitive or meta-cognitive or milieu or morita or multimodal or multi-modal or music or narrative or nondirective or non-directive or “non directive” or nonspecific or non-specific or “non specific” or “object relations” or “personal construct” or “person cent*” or person-cent* or persuasion or play or “pleas* event*” or primal or problem-focused or “problem focused” or problem-solving or “problem solving” or process-experiential or “process experiential” or psychodynamic or “rational emotive” or reality or “reciprocal inhibition” or relationship* or reminiscence or restructuring or rogerian or schema* or self-control* or “self control*” or “short term” or short-term or sex or “social effectiveness” or “social skill*” or socio-environment* or “socio environment*” or “solution focused” or solution-focused or “stress management” or supportive or time-limited or “time limited” or “third wave” or transference or transtheoretical or validation)) or abreaction or “acting out” or “age regression” or ((assertive* or autogenic or mind or sensitivity) and train*) or autosuggestion or “balint group” or ((behavior* or behaviour*) and (activation or therap* or treatment or contracting or modification)) or biofeedback or catharsis or cognitive or “mind training” or counsel* or “contingency management” or countertransference or “covert sensitization” or “eye movement desensiti*” or “crisis intervention” or “dream analysis” or “emotional freedom” or “free association” or “functional analys*” or griefwork or “guided imagery” or hypno* or imagery or meditation* or “mental healing” or mindfulness* or psychoanaly* or psychodrama or psychoeducat* or “psycho* support*” or psychotherap* or relaxation or “role play*” or “self analysis” or “self esteem” or “sensitivity training” or “support* group*” or therapist or “therapeutic technique*” or “transactional analysis”)

Additional references

- APA 1980 . American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-III)*. 3rd Edition. American Psychiatric Association; Washington DC: 1980.
- APA 1987 . American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)*. 3rd Edition. American Psychiatric Association; Washington DC: 1987.
- APA 1994 . American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)*. 4th Edition. American Psychiatric Association; Washington DC: 1994.

- APA 2000 . American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)*. 4th Edition. American Psychiatric Association; Washington DC: 2000.
- Arroll 2009 . Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care. *Cochrane Database of Systematic Reviews*. 2009; (3) DOI: 10.1002/14651858.CD007954.
- Ballenger 2001 . Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ. A Proposed Algorithm for Improved Recognition and Treatment of the Depression/Anxiety Spectrum in Primary Care. *Primary Care Companion to the Journal of Clinical Psychiatry*. 2001; 3(2):44–52.
- Barbato 2006 . Barbato A, D'Avanzo B. Marital therapy for depression. *Cochrane Database of Systematic Reviews*. 2006; (2) DOI: 10.1002/14651858.CD004188.pub2.
- Barrett-Lennard 1986 . Barrett-Lennard, GT. The relationship inventory now: Issues and advances in theory, method and use. *The Psychotherapeutic Process: A Research Handbook*. Greenberg, LS.; Pinsof, W., editors. Guilford Press; New York: 1986.
- Bayer 2000 . Bayer A, Tadd W. Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval: descriptive study. *BMJ*. 2000; 321(7267):992–3. [PubMed: 11039965]
- Beck 1961 . Beck AT, Ward CH, Mendelsohn M, Mock J, Erbaugh J. An inventory for measuring depression. *Archives of General Psychiatry*. 1961; 4:561–71. [PubMed: 13688369]
- Beck 1979 . Beck, AT.; Rush, AJ.; Shaw, BF.; Emery, G. *Cognitive Therapy of Depression*. Guilford Press; New York: 1979.
- Beck 1988 . Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. *Journal of Consulting and Clinical Psychology*. 1988; 56(6):893–7. [PubMed: 3204199]
- Becker 2009 . Becker, LA.; Oxman, AD. Chapter 22: Overviews of reviews. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]*. Higgins, JPT.; Green, S., editors. The Cochrane Collaboration; 2008. Available from www.cochrane-handbook.org
- Berne 1961 . Berne, E. *Transactional analysis in psychotherapy*. Grove Press; New York: 1961.
- Bugental 1978 . Bugental, JFT. *Psychotherapy and process: the fundamentals of an existential-humanistic approach*. McGraw-Hill; Boston MA: 1978.
- Cain 2002 . Cain, DJ.; Seeman, J. *Humanistic Psychotherapies: Handbook of Research and practice*. American Psychological Association; Washington DC: 2002.
- Caldwell 2005 . Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ*. 2005; 331(7521):897–900. [PubMed: 16223826]
- Chen 2001 . Chen YF, Dewey ME, Avery AJ. Self-reported medication use for older people in England and Wales. *Journal of Clinical Pharmacy and Therapeutics*. 2001; 26(2):129–40. [PubMed: 11350536]
- Churchill 2000 . Churchill R, Khaira M, Grettton V, Chilvers C, Dewey M, Duggan C, et al. Treating depression in general practice: factors affecting patients' treatment preferences. *British Journal of General Practice*. 2000; 50(460):905–6. [PubMed: 11141877]
- Churchill 2001 . Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A, et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. *Health Technology Assessment*. 2001; 5(35):1–173. [PubMed: 12387733]
- Cipriani 2005 . Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, et al. Fluoxetine versus other types of pharmacotherapy for depression. *Cochrane Database of Systematic Reviews*. 2005; (4) DOI: 10.1002/14651858.CD004185.pub2.
- Cipriani 2009a . Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, et al. Escitalopram versus other antidepressive agents for depression. *Cochrane Database of Systematic Reviews*. 2009; (2) DOI: 10.1002/14651858.CD006532.pub2.
- Cipriani 2009b . Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, et al. Sertraline versus other antidepressive agents for depression. *Cochrane Database of Systematic Reviews*. 2009; (2) DOI: 10.1002/14651858.CD006117.pub4.

- Cipriani 2009c . Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet*. 2009; 373(9665):746–58. [PubMed: 19185342]
- Cooper 2003 . Cooper, M. *Existential therapies*. Sage; London: 2003.
- Cooper 2008 . Cooper, M. *Essential Research Findings in Counselling and Psychotherapy. The Facts are Friendly*. Sage; London: 2008.
- Cuijpers 2002 . Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. *Journal of Affective Disorders*. 2002; 72:227–236. [PubMed: 12450639]
- Cuijpers 2008 . Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. *Journal of Consulting and Clinical Psychology*. 2008; 76(6):909–22. [PubMed: 19045960]
- De Shazer 1988 . De Shazer, S. *Clues: investigating solutions in brief therapy*. WW Norton; New York: 1988.
- Deeks 1997 . Deeks JJ. Are you sure that's a standard deviation? (part 1). *Cochrane News*. 1997; 10:11–2.
- Deeks 2008 . Deeks, JJ.; Higgins, JPT.; Altman, DG.; On behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2* [updated September 2009]. Higgins, JPT.; Green, S., editors. The Cochrane Collaboration: 2008. Available from www.cochrane-handbook.org
- Elliott 2009 . Elliott, R.; Freire, B. [Accessed April 2010] Person-centred/experiential therapies are highly effective: summary of the 2008 meta-analysis. British Association for the Person-Centred Approach. 2009. Available from: <http://www.bapca.co.uk>
- Ellis 2004 . Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. *Australian and New Zealand Journal of Psychiatry*. 2004; 38(6):389–407. [PubMed: 15209830]
- ESEMeD/MHEDEA 2004 . ESEMeD/MHEDEA 2000 investigators. Prevalence of mental disorders in Europe: results from the European Study of Epidemiology of Mental Disorders (ESEMeD) project. *Acta Psychiatrica Scandinavica*. 2004; 109(s420):21–7.
- Frankl 1984 . Frankl, VE. *Man's search for meaning*. Washington Square Press; New York: 1984.
- Freud 1949 . Freud, S. *An outline of psychoanalysis*. Hogarth Press; London: 1949.
- Furukawa 2005 . Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. *Internal Clinical Psychopharmacology*. 2005; 20:49–52.
- Furukawa 2006 . Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. *Journal of Clinical Epidemiology*. 2006; 59:7–10. [PubMed: 16360555]
- Gendlin 1996 . Gendlin, ET. *Focusing-oriented psychotherapy*. Guildford; New York: 1996.
- Greenberg 1998 . Greenberg LS, Watson J. Experiential therapy of depression: Differential effects of client-centered relationship conditions and process experiential interventions. *Psychotherapy Research*. 1998; 8(2):210–24.
- Greenberg 2005 . Greenberg, LS.; Watson, J. *Emotion-focused therapy of depression*. American Psychological Association; Washington DC: 2005.
- Greenberg 2006 . Greenberg LS, Pascual-Leone A. Emotion in psychotherapy: a practice-friendly research review. *Journal of Clinical Psychology*. 2006; 62(5):611–30. [PubMed: 16523500]
- Guaiana 2007 . Guaiana G, Barbui C, Hotopf M. Amitriptyline for depression. *Cochrane Database of Systematic Reviews*. 2007; (3) DOI: 10.1002/14651858.CD004186.pub2.
- Guy 1976 . Guy, W. *ECDEU assessment manual for psychopharmacology*. Division of Extramural Research Programs; NIMH Psychopharmacology Research Branch: 1976. p. 218–22.
- Hamilton 1959 . Hamilton M. The assessment of anxiety states by rating. *British Journal of Medical Psychology*. 1959; 32(1):50–5. [PubMed: 13638508]
- Hamilton 1960 . Hamilton M. A rating scale for depression. *Journal of Neurology, Neurosurgery, and Psychiatry*. 1960; 23:56–62.

- Hamilton 1967 . Hamilton M. Development of a rating scale for primary depressive illness. *British Journal of Social & Clinical Psychology*. 1967; 6(4):278–96. [PubMed: 6080235]
- Henken 2007 . Henken HT, Huibers MJ, Churchill R, Restifo K, Roelofs J. Family therapy for depression. *Cochrane Database of Systematic Reviews*. 2007; (3) DOI: 10.1002/14651858.CD006728.
- Higgins 2003 . Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003; 327(7414):557–60. [PubMed: 12958120]
- Higgins 2008 . Higgins, JPT.; Green, S. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2* [updated September 2009]. The Cochrane Collaboration; 2008. Available from www.cochrane-handbook.org
- Higgins 2008a . Higgins, JPT.; Altman, DG.; On behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins, JPT.; Green, S., editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2* [updated September 2009]. The Cochrane Collaboration; 2008. Available from www.cochrane-handbook.org
- Higgins 2008b . Higgins, JPT.; Deeks, JJ.; Altman, DG.; On behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins, JPT.; Green, S., editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2* [updated September 2009]. The Cochrane Collaboration; 2008. Available from www.cochrane-handbook.org
- Horvath 1986 . Horvath, AO.; Greenberg, L. The development of the Working Alliance Inventory: A research handbook. In: Greenberg, L.; Pinsoff, W., editors. *Psychotherapeutic Processes: A Research Handbook*. Guildford Press; New York: 1986.
- Hunot 2007 . Hunot VM, Home R, Leese MN, Churchill RC. A Cohort Study of Adherence to Antidepressants in Primary Care: The Influence of Antidepressant Concerns and Treatment Preferences. *Primary Care Companion to the Journal of Clinical Psychiatry*. 2007; 9(2):91–9.
- Ivnik 1992 . Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E. Mayo's older American normative studies: updated AVLT norms for age 56–97. *Clinical Neuropsychologist*. 1992; 6(s1):82–103.
- Jung 1963 . Jung, CG. *Memories, Dreams, Reflections*. Collins and Routledge; London: 1963.
- Klein 1960 . Klein, M. *Our Adult World and its Roots in Infancy*. Tavistock; London: 1960.
- Klerman 1984 . Klerman, GL.; Weissman, MM.; Rounsaville, BJ.; Chevron, ES. *Interpersonal Psychotherapy for Depression*. Basic Books; New York: 1984.
- Law 2003 . Law J, Garrett Z, Nye C. Speech and language therapy interventions for children with primary speech and language delay or disorder. *Cochrane Database of Systematic Reviews*. 2003; (3) DOI: 10.1002/14651858.CD004110.
- Lazarus 1971 . Lazarus, AA. *Behavior Therapy and Beyond*. McGraw-Hill; New York: 1971.
- Lu 2004 . Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Statistics in Medicine*. 2004; 23(20):3105–24. [PubMed: 15449338]
- Luborsky 1962 . Luborsky L. Clinician's judgments of mental health. *Archives of General Psychiatry*. 1962; 7:407–17. [PubMed: 13931376]
- Marks 1981 . Marks, IM. *Cure and Care of Neuroses: Theory and Practice of Behavioural Psychotherapy*. John Wiley & Sons; Chichester: 1981.
- Maslow 1943 . Maslow AH. A theory of human motivation. *Psychological Review*. 1943; 50:270–96.
- Maslow 1959 . Maslow, AH. *New Knowledge in Human Values*. HarperCollins; 1959.
- Maslow 1970 . Maslow, AH. *Motivation and personality*. Harper & Row; New York: 1970.
- May 1961 . May, R., editor. *Existential Psychology*. Random House; New York: 1961.
- McMurdo 2005 . McMurdo ME, Witham MD, Gillespie ND. Including older people in clinical research. *BMJ*. 2005; 331(7524):1036–7. [PubMed: 16269472]
- Mearns 2007 . Mearns, D.; Thorne, B. *Person-Centred Counselling in Action*. Sage; London: 2007.
- Mitchell 2009 . Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. *The Lancet*. 2009; 374(9690):609–19.

- Montgomery 1979 . Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *British Journal of Psychiatry*. 1979; 134:382–9. [PubMed: 444788]
- Mykletun 2009 . Mykletun A, Bjerkeset O, Øverland S, Prince M, Dewey M, Stewart R. Levels of anxiety and depression as predictors of mortality: the HUNT study. *British Journal of Psychiatry* (2009). 2009; 195:118–125.
- NICE 2009 . National Institute for Health and Clinical Excellence (NICE). Depression: treatment and management of depression in adults, including adults with a chronic physical health problem. Clinical Guidelines 90 and 91. NICE; London: 2009. Available from: www.nice.org.uk/CG91 [Accessed April 2010]
- O'Connell 2007 . O'Connell, B. Solution-focused therapy. In: Dryden, W., editor. *Dryden's Handbook of Individual Therapy*. 5th Edition. Sage Publications Ltd; London: 2007.
- Perls 1976 . Perls, F. *The Gestalt approach and eye witness to therapy*. Bantam Books; New York: 1976.
- Pilgrim 2002 . Pilgrim, D. The Cultural Context of British Psychotherapy. In: Dryden, W., editor. *Dryden's Handbook of Individual Psychotherapy*. 4th Edition. Sage; London: 2002.
- Rait 2005 . Rait G, Fletcher A, Smeeth L, Brayne C, Stirling S, Nunes M, et al. Prevalence of cognitive impairment: results from the MRC trial of assessment and management of older people in the community. *Age and Ageing*. 2005; 34(3):242–8. [PubMed: 15863409]
- Rait 2009 . Rait G, Walters K, Griffin M, Buszewicz M, Petersen I, Nazareth I. Recent trends in the incidence of recorded depression in primary care. *The British Journal of Psychiatry*. 2009; 195(6):520–4. [PubMed: 19949202]
- Riedel-Heller 2005 . Riedel-Heller SG, Matschinger H, Angermeyer MC. Mental disorders--who and what might help? Help-seeking and treatment preferences of the lay public. *Social Psychiatry and Psychiatric Epidemiology*. 2005; 40(2):167–74. [PubMed: 15685409]
- Roca 2009 . Roca M, Gili M, Garcia-Garcia M, Salva J, Vives M, Garcia Campayo J, et al. Prevalence and comorbidity of common mental disorders in primary care. *Journal of Affective Disorders*. 2009; 119(1-3):52–8. [PubMed: 19361865]
- Rogers 1951 . Rogers, C. *Client-centered therapy: Its current practice, implications and theory*. Constable; London: 1951.
- Ryle 1990 . Ryle, A. *Cognitive-analytic Therapy - Active Participation in Change: New Integration in Brief Psychotherapy*. John Wiley & Sons; Chichester: 1990.
- Sanders 2007 . Sanders, P. The 'family' of person-centred and experiential therapies. In: Cooper, M.; Scmid, PF.; O'Hara, M.; Wyatt, G., editors. *The Handbook of Person-Centered Psychotherapy and Counselling*. Palgrave; London: 2007.
- Skinner 1953 . Skinner, BF. *Science and human behaviour*. Free Press; New York: 1953.
- Spielberger 1983 . Spielberger, CD.; Gorsuch, RL.; Lushene, R.; Vagg, PR.; Jacobs, GA. *Manual for the State-Trait Anxiety Inventory*. Consulting Psychologists Press; Palo Alto, CA: 1983.
- Stiles 2008 . Stiles WB, Barkham M, Mellor-Clark J, Connell J. Effectiveness of cognitive-behavioural, person-centred, and psychodynamic therapies in UK primary-care routine practice: replication in a larger sample. *Psychological Medicine*. 2008; 38(5):677–88. [PubMed: 17825124]
- Strumpf 2006 . Strumpf, U.; Goldman, R. Contacting gestalt therapy. In: Cain, DJ.; Seeman, J., editors. *Humanistic psychotherapies: Handbook of research and practice*. 3rd Edition. APA; Washington: 2006.
- Thorne 2002 . Thorne, B. Person-centred therapy. In: Dryden, W., editor. *The Handbook of Individual Therapy*. 4th Edition. Sage; London: 2002. p. 584
- Thorne 2007 . Thorne, B. Person-centred therapy. In: Dryden, W., editor. *Dryden's handbook of individual therapy*. 5th Edition.. Sage: 2007.
- Tudor 2002 . Tudor, K.; Hobbess, R. Transactional Analysis. In: Dryden, W., editor. *The Handbook of Individual Therapy*. 4th Edition. Sage; London: 2002. p. 484
- Ustun 2004 . Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. *British Journal of Psychiatry*. 2004; 184:386–92. [PubMed: 15123501]

- van Deurzen 1997 . van Deurzen, E. *Everyday Mysteries: Existential Dimensions of Psychotherapy*. Routledge; London: 1997.
- van Deurzen 2002 . van Deurzen, E. *Existential Therapy*. *The Handbook of Individual Therapy*. 4th Edition. Dryden, W., editor. Sage; London: 2002. p. 584
- van Geffen 2009 . van Geffen EC, Gardarsdottir H, van Hulten R, van Dijk L, Egberts AC, Heerdink ER. Initiation of antidepressant therapy: do patients follow the GP's prescription? *British Journal of General Practice*. 2009; 59(559):81–7. [PubMed: 19192372]
- Ware 1993 . Ware, JE.; Snow, KK.; Kosinski, M.; Gandek, B. *SF-36 Health Survey: Manual and interpretation guide*. Health Institute, New England Medical Center; Boston, MA: 1993.
- Warner 2000 . Warner MS. Person-centered psychotherapy: one nation many tribes. *Person Centered Journal*. 2000; 7(1):28–39.
- Watanabe 2004 . Watanabe N, Churchill R, Hunot V, Furukawa TA. Psychotherapy for depression in children and adolescents. *Cochrane Database of Systematic Reviews*. 2004; (4) DOI: 10.1002/14651858.CD005334.
- Watson 1924 . Watson, JB. *Behaviorism*. Norton; New York: 1924.
- Watzlavick 1974 . Watzlavick, P.; Weakland, J.; Fisch, R. *Brief Problem Solving Change: principles of problem formation and problem resolution*. W W Norton; New York: 1974. *Change: principles of problem formation and problem resolution*. New York: W W Norton
- Welton 2009 . Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. *American Journal of Epidemiology*. 2009; 169(9):1158–65. [PubMed: 19258485]
- WHO 1978 . World Health Organisation (WHO). *The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9)*. WHO; Geneva: 1978.
- WHO 1992 . World Health Organisation (WHO). *The ICD-10 Classification of Mental and Behavioural Disorders*. WHO; Geneva: 1992.
- WHO 2001 . World Health Organisation (WHO). *World Health Report 2001: Mental Health: New Understanding, New Hope*. WHO; Geneva: 2001.
- WHO 2004 . WHO. *The global burden of disease: 2004 update*. WHO; Geneva: 2004.
- WHO 2008 . WHO. 2008. http://www.who.int/healthinfo/global_burden_disease/projections/en/index.html
- WHOQOL 1998 . WHOQOL Group. The World Health Organisation Quality of Life Assessment (WHOQOL): development and general psychometric properties. *Social Science and Medicine*. 1998; 46:1569–85. [PubMed: 9672396]
- Wilson 2008 . Wilson KC, Mottram PG, Vassilas CA. Psychotherapeutic treatments for older depressed people. *Cochrane Database of Systematic Reviews*. 2008; (1) DOI: 10.1002/14651858.CD004853.pub2.
- Wing 1994 . Wing, J. *Measuring mental health outcomes: a perspective from the Royal College of Psychiatrists*. *Outcomes into Clinical Practice*. BMJ publishing; London: 1994.
- Yalom 1980 . Yalom, I. *Existential Psychotherapy*. Basic Books; New York: 1980.
- Yontef 1998 . Yontef, G. *Dialogic gestalt therapy*. *Handbook of experiential psychotherapy*. Greenberg, LS.; Watson, J.; Lietaer, G., editors. Guilford Press; New York: 1998.

**Indicates the major publication for the study*